Journal article
Inflammatory biomarkers in Alzheimer's disease plasma.
-
Morgan AR
Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
-
Touchard S
Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
-
Leckey C
Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
-
O'Hagan C
Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
-
Nevado-Holgado AJ
Department of Psychiatry, University of Oxford, Oxford, UK.
-
Barkhof F
Max Planck Institute for Molecular Genetics, Berlin, Germany.
-
Bertram L
Aix-Marseille University, APHM, Institute Neurosci System, Pharmacology, Marseille, France.
-
Blin O
Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
-
Bos I
Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany.
-
Dobricic V
Department of Neurology, Hospital Network Antwerp (ZNA), Antwerp, Belgium; Reference Center for Biological Markers of Dementia, Institute Born-Bunge, Antwerp, Belgium.
-
Engelborghs S
University of Geneva, Geneva, Switzerland; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
-
Frisoni G
Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.
-
Frölich L
Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
-
Gabel S
Division of Clinical Geriatrics, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
-
Johannsen P
University of Gothenburg, Institute of Neuroscience and Physiology, Gothenburg, Sweden.
-
Kettunen P
Department of Old Age Psychiatry & Psychotic Disorders, Medical University of Lodz, Lodz, Poland.
-
Kłoszewska I
UCL Institutes of Neurology and Healthcare Engineering, University College London, London, UK; School of Public Health, Imperial College London, London, UK.
-
Legido-Quigley C
Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
-
Lleó A
CITA-Alzheimer Foundation, San Sebastian, Spain.
-
Martinez-Lage P
Department of Medicine, Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy.
-
Mecocci P
Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
-
Meersmans K
Barcelona Beta Brain Research Center, Unversitat Pompeu Fabra, Barcelona, Spain.
-
Molinuevo JL
Department of Psychiatry, Old Age Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.
-
Peyratout G
Hopitaux Universitaires Geneve and Universite de Geneve, Geneva, Switzerland.
-
Popp J
Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK.
-
Richardson J
Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
-
Sala I
Alzheimer Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands.
-
Scheltens P
Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
-
Streffer J
Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.
-
Soininen H
Center for Research and Advanced Therapies. CITA-Alzheimer Foundation, San Sebastian, Spain.
-
Tainta-Cuezva M
University Hospital Leuven, Leuven, Belgium.
-
Teunissen C
1st Department of Neurology, AHEPA University Hospital, Makedonia, Thessaloniki, Greece.
-
Tsolaki M
Department of Clinical Chemistry, Neurochemistry lab, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
-
Vandenberghe R
Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
-
Visser PJ
Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
-
Vos S
NVS-Department, Section of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden.
-
Wahlund LO
Section for Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.
-
Wallin A
Department of Psychiatry, University of Oxford, Oxford, UK.
-
Westwood S
Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; UK Dementia Research Institute, London, UK.
-
Zetterberg H
Department of Psychiatry, University of Oxford, Oxford, UK.
-
Lovestone S
Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK. Electronic address: morganbp@cardiff.ac.uk.
-
Morgan BP
Show more…
Published in:
- Alzheimer's & dementia : the journal of the Alzheimer's Association. - 2019
English
INTRODUCTION
Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.
METHODS
A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.
RESULTS
Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).
DISCUSSION
Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
-
Language
-
-
Open access status
-
hybrid
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/279594
Statistics
Document views: 60
File downloads: